logo
Plus   Neg
Share
Email

LSEG Says Raffaele Jerusalmi, Andrea Sironi To Step Down From Board - Quick Facts

London Stock Exchange Group plc (LSE.L) said Friday that shareholders in Euronext N.V. (ENXB.BE,ENX.BR,ENX.AS,ENX.PA) have approved the proposed acquisition of London Stock Exchange Group Holdings Italia S.p.A. together with its subsidiaries, the Borsa Italiana Group.

In preparation for the proposed divestment of the Borsa Italiana Group to Euronext, Raffaele Jerusalmi and Andrea Sironi have agreed to step down from the LSEG plc Board with immediate effect.

"On behalf of the Board, I would like to thank Raffaele and Andrea for the tremendous contributions they have made both to the Group's success in Italy and more broadly. Raffaele, in the last 10 years in his role as an Executive Director, has played a key role in the growth of the Group's Capital Markets business since the merger between Borsa Italiana and London Stock Exchange in 2007," said Don Robert, Chair of LSEG.

In October, London Stock Exchange said it agreed to sell its entire shareholding in London Stock Exchange Group Holdings Italia S.p.A, the parent company of Borsa Italiana, to Euronext for an equity value of 4.325 billion euros, plus an additional amount reflecting cash generation to completion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
RELATED NEWS
Follow RTT